We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Scientific Advisory Board > Professor Mikael Kubista

Professor Mikael Kubista

Founder, TATAA Biocenter

Professor Mikael Kubista obtained a BSc in chemistry at the University of Göteborg, Sweden, in 1984. After working at Astra Hässle (today part of AstraZeneca), he returned to academia, joining Chalmers University of Technology in Göteborg and received a PhD in 1988 for studies of nucleic acid interactions with polarized light spectroscopy. This was followed by post-doctoral positions at La Trobe University, Melbourne, Australia, and Yale University, New Haven, USA.

In 1991, Kubista started his own research group studying DNA-ligand interactions. His group discovered a novel mechanism of transcriptional activation of oncogenes, developed methods for multidimensional data analysis based on which MultiD Analyses AB was founded, and invented the light-up probes for nucleic acid detection in homogeneous solution, which led to the foundation of LightUp Technologies AB as Europe´s first company focusing on quantitative real-time PCR (qPCR) based diagnostics.

In 2001 Kubista set up the TATAA Biocenter as a center of excellence in qPCR and gene expression analysis with locations in Gothenburg, Sweden and Prague, Czech Republic. In 2014 TATAA introduced non-invasive prenatal testing (NIPT) in Sweden and separated the business into the company Life Genomics AB.

Kubista also co-authored the MIQE guidelines for RT-qPCR analysis, which has had over 5000 citations, and became a member of the CEN/ISO working group that developed the guidelines for the pre-analytical process in molecular diagnostics that came in force during 2015. Since 2007 Kubista heads the Department of Gene Expression at the Institute of Biotechnology, CAS.